Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

261

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Type 2 Diabetes
Interventions
DRUG

placebo

subcutaneous injection, twice a day

DRUG

exenatide

subcutaneous injection, twice a day, 10mcg

Trial Locations (59)

Unknown

Research Site, Peoria

Research Site, Phoenix

Research Site, Buena Park

Research Site, Concord

Research Site, Fresno

Research Site, Greenbrae

Research Site, La Mesa

Research Site, Lancaster

Research Site, Northridge

Research Site, Palm Springs

Research Site, Salinas

Research Site, Hollywood

Research Site, Jacksonville

Research Site, Atlanta

Research Site, Honolulu

Research Site, Idaho Falls

Research Site, Des Moines

Research Site, Wichita

Research Site, Baton Rouge

Research Site, Lafayette

Research Site, Matairie

Research Site, Boston

Research Site, Minneapolis

Research Site, Chesterfield

Research Site, St Louis

Research Site, Omaha

Research Site, Las Vegas

Research Site, Berkeley Heights

Research SIte, Teaneck

Research Site, Albuquerque

Research SIte, New York

Research Site, Durham

Research Site, Bend

Research Site, Dallas

Research Site, El Paso

Research Site, Georgetown

Research Site, San Antonio

Research Site, Richmond

Research Site, Vancouver

Research Site, Kenosha

Research Site, Athens

Research Site, Thessaloniki

Research Site, Holon

Research Site, Kfar Saba

Research Site, Tel Litwinsky

Research Site, Coatzacoalcos

Research Site, Monterrey

Research Site, México

Research Site, Carolina

Research Site, Hato Rey

Research Site, Ponce

Research Site, San Juan

Research Site, Birmingham

Research Site, Guildford

Research Site, Leicester

Research Site, Livingston

Research Site, Middlesbrough

Research Site, Swansea

Research Site, Torquay

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY

NCT00765817 - Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter